A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 601–700 of 720
Prevención de la obesidad infantil: Problemática pandémica y atención sociosanitaria
Martín, R. A., & de Arenas, P. C. N. (2025) · Enfermería en cardiología: revista científica e informativa de la Asociación Española de Enfermería en Cardiología · doi:10.59322/92.1726.va2
Rossi, F. A. M., Aristizábal, E. A., Saleh, K., Sánchez, D. A., Castro, N. I. Q., Coronel, J., Villota, L. A., Gonzalez, J. D., Ibarra, D. A., & Ossio, G. P. R. (2025) · Cureus · doi:10.7759/cureus.83738 · Cited by 1
“To evaluate these conclusions, we performed a sensitivity analysis systematically excluding Kelly et al. [22], which did not significantly alter the effect estimate.”
InfluentialNguyen, J., Espinoza, J., Babaei, M., Vu, M. H., Black, D. S., & Vidmar, A. P. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2024.0002
Kovtun, O. P., Ustiuzhanina, M. A., Solodushkin, S. I., Kovalchuk, L. V., & Zaslavskaya, K. Y. (2025) · Педиатрическая фармакология · doi:10.15690/pf.v22i2.2871 · Cited by 1
Aamir, A. B., Latif, R., Fallatah, J. O., Alqoofi, J. F., Alsalman, H. A., & Almarzoq, F. A. (2025) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2024-0196 · Cited by 1
Chigurupati, M. (2025) · Journal of medical and dental science research. · doi:10.35629/076x-12039499
Pediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Kunam, L., Sweeney, B. R., Fischer, R. T., Campbell, N., Fraser, J. D., Hendrickson, R. J., Mullapudi, B., Kotecha, M., Dreyer, M. L., & Slowik, V. (2025) · Pediatric Transplantation · doi:10.1111/petr.70124
“Liraglutide is associated with a reduction from base-line BMI of approximately 5% in both 6–12 years of age and 12–18 years of age [25, 26].”
Avances en el tratamiento farmacológico de las obesidades infantiles
Oliver, J. A. (2025) · Pediatría Integral · doi:10.63149/j.pedint.39
Phan, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_15
Novità sulle terapie farmacologiche per l’obesità pediatrica
Buganza, R., & Massini, G. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01648-3
“Il principale studio pediatrico [14], pubblicato nel 2020 su 251 adolescenti (12–18 anni), ha evidenziato, dopo 56 settimane, una riduzione del BMI del 4,29% con liragluti-de, rispetto all’aumento dello 0,35% con placebo; anche la percentuale dei soggetti che hanno ottenuto una riduzione del BMI ≥…”
InfluentialNeue Therapien bei Adipositas im Kindesalter
Gomahr, J., & Weghuber, D. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00271-9
Nonalcoholic Fatty Liver Disease
Choi, Y., & Feldstein, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00075-6
Head, K. C., & Giovanni, C. B. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00014-8
The evolving landscape of pediatric hepatology: key updates and future directions
Lu, P. M., Ovchinsky, N., & Goldner, D. L. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001489
Adipositas bei Kindern und Jugendlichen
Wabitsch, M. (2025) · Springer Reference Medizin · doi:10.1007/978-3-642-54671-6_33-3
Metabolomic, Lipidomic, and Enterohormone Changes in the Progression from MASLD to MASHPreprint
Rivas, J. A., Murphy, A. C., Prasad, P., Goitom, S. S., Romero, A. S., Enriquez, C. M., Maes, B. B., Akepati, P. R., Garcia, M. A., Lauer, F. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676598
Burr, E. F., Roytman, M., Poirier, É., Kolbuszewska, M. T., Pfaus, J. G., Komisaruk, B. R., Goldstein, I., & Rubin, R. S. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf073 · Cited by 3
Адипокины и их роль в патогенезе детского ожирения
Хавкин, А. И., Shrayner, E. V., & Новикова, В. П. (2025) · Children s medicine of the North-West · doi:10.56871/cmn-w.2025.85.14.009
Treatment Options for Polycystic Ovary Syndrome
Cai, J., Lü, N., & Ma, J. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1012822 · Cited by 1
Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism
Joly, A., Rebiffé, L., Dusabyinema, Y., Dellinger, J., Caillon, E., Gauthier, K. C., Leulier, F., & Vadder, F. D. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf158 · Cited by 2
Cherednikova, K. A., Bolotova, N. V., Filina, N. Y., Polyakov, V. K., Sharapova, M. A., Kompaniets, O. V., & Averianov, A. P. (2025) · Pediatrics Consilium Medicum · doi:10.26442/26586630.2025.3.203357
Adipositas und Diabetes: Was kann man in der Praxis tun?
Weiner, S. R. (2025) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-025-5340-6
Chinn, J. O., Shacker, M., Brennan, K., Kochis, M. A., Stetson, A. E., Bizimana, C., Filho, J. R. D. O., Hornick, M. A., Pratt, J. S. A., Haija, M. A. E., et al. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.10.014 · Cited by 1
Petlansky, R., & Graber, E. (2025) · Case Reports in Pediatrics · doi:10.1155/crpe/1707315
“…trial published in 2020 found lir-aglutide more efective than placebo in weight loss at 1 year among patients 12 years and older with obesity who did not respond to lifestyle treatment, and liraglutide was subsequently approved for use for weight loss in children and adolescents [11, 12].”
Kim, R., & Benden, E. (2025) · Springer eBooks · doi:10.1007/978-3-031-97759-6_37
Futuros fármacos, nuevas indicaciones y vacunas COVID-19
Núñez, A. N.-T., & Landesa, S. A. (2021) · Actualización en Medicina de Familia · doi:10.55783/amf.170910
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. (2024) · Figshare · doi:10.6084/m9.figshare.26157034
大正期社会主義思想における「階級」とナショナリズムの問題 : 堺利彦と雑誌『新社会』を中心に
Qian, X. (2003) · Institutional Repositories DataBase (IRDB) · doi:10.14988/pa.2017.0000010610
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26680684
López, G. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107122 · Cited by 2
Anti-obesity Pharmacotherapy for Patients with Genetic Obesity Disorders
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-04095-4_15
Stephenson, K. M., Schwartz, N. R. M., Person, H., Blondet, N. M., Benitez-Cortez, M., Nuding, M. E., Kraft, S. A., & Suskind, D. L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.52825
Łuczak, P. M., Perediatkiewicz, J., Liszka, P., Puchalski, K. R., Patrzykąt, K. M., Olejnik-Chlewicka, K. M., Urbański, W., Zasiadła, M., Brodowski, J., & Ogorek, A. (2026) · Cureus · doi:10.7759/cureus.101545 · Cited by 2
Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity
Wen, H. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1684485
Patri, J. R., Chamarthi, V. S., Kapoor, V., & Gunasekaran, V. (2026) · International Journal of Contemporary Pediatrics · doi:10.18203/2349-3291.ijcp20260056
Gupta, S., Lal, P., Gupta, A., & Chaudhary, B. R. (2026) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.02838
Tou, A. M., & Panganiban, J. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115011
Khalil, H., Feigin, E., & Zaitoon, H. (2026) · Pediatric Investigation · doi:10.1002/ped4.70040 · Cited by 1
“58–60 Although their effects in syndromic obesity, such as PWS, are inconsistent, 61 they should be used with caution in children.”
Phytochemical Mechanisms of Action Against Obesity and Strategies to Overcome Limitations
Thi, N. H. L., Park, S. Y., Lee, J., Hwang, Y.-S., Kim, S. J., Choi, Y.-J., Kim, M.-H., & Kang, K. S. (2026) · Perspectives on Integrative Medicine · doi:10.56986/pim.2026.02.003
“…which is a glucagon-like peptide-1 receptor agonist, was approved for obesity treatment in the US in 2015; it regulates blood sugar, suppresses appetite, slows gastric emptying, and results in a mean body mass index reduction of 5%, however, it primarily causes gastrointestinal issues [9].”
Predicting Weight Outcomes From Obesity Medications in a Paediatric Population
Mottalib, M. M., Beheshti, R., Viswanathan, K., Bunnell, H. T., & Phan, T.-L. T. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70089 · Cited by 3
“In clinical trials, 73% of adolescents receiving Semaglutide [7], 43% receiving Liraglutide [8] and 47% receiving Phentermine/Topiramate had a BMI loss of greater than 5% [9].”
Diaz, M. E. C., Kim, G., & Vakharia, M. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156317
Disparities in Medication Treatment of Type 2 Diabetes and Obesity
Whooten, R., Allen, L., & Stanford, F. C. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074840
Pharmacotherapy in childhood obesity: Key points from the 2023 AAP clinical practice guideline
Alam, F., & Newbern, D. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151608
Current updates and anesthetic considerations for adolescent metabolic and bariatric surgery
Doyle, N. M., Weisberg, E. L., Glenski, T. A., & Taylor, C. M. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151610
BEYOND THE SCALE: COMPREHENSIVE TREATMENT OPTIONS FOR YOUTH OBESITY
Jabłonowska, M., & Grzeszczuk, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4236
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity
KURAN, Ö., & Cömert, T. K. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00370-y
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Nueva era terapéutica en la obesidad infantojuvenil: oportunidades y retos de futuro
Molina-Giraldo, P., Suárez-Ortega, L., & Ramon‐Krauel, M. (2026) · Anales de Pediatría · doi:10.1016/j.anpedi.2026.504194
Metabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)
Joseph, A. (2021) · theses.fr (ABES) · doi:10.70675/b045685ezd444z4b46zb0f9z0e726ceac466
Hunter, T. M., Leith, A., Harrison, L., Gerber, C., Raikar, S. K., Ashok, G., & Artime, E. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03580-w
“Clinical findings have reported that newer OMMs, including tirzepa-tide, have clinically meaningful weight reduction among PwO [16, 31, 32].”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03599-z · Cited by 1
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
“The largest trial included 251 pubertal adolescents (12 to 18 years of age) with obesity and tested liraglutide 3.0 mg against placebo for 56 weeks of treatment [33].”
InfluentialIlyas, A. (2026) · Premier journal of public health. · doi:10.70389/pjph.100026
Pharmacological interventions for the treatment of obesity in children and adolescents
Gerardi, C., Allocati, E., Prutsky, G. J., Carrano, F. M., Romano, E., Giorgi, S. D., Metzendorf, M., Calcaterra, V., Lorenzo, N. D., & Banzi, R. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015986 · Cited by 2
Losordo, L. D., Amin, G., Singla, M., Belk, S. S., Butler, K. R., Booz, G. W., & Monafo, A. (2026) · Pediatric Research · doi:10.1038/s41390-026-05038-9
“91 Fox et al. reported similar conclusions in a randomized controlled trial that included pediatric patients from a younger age, 6–12 years, showcasing the preliminary efficacy of GLP-1 RA in populations younger than those currently approved by the FDA.”
Assessment and treatment of binge eating disorder in adolescence
Smith, M. R., Chevinsky, J. D., & Jhe, G. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001562
Tan, A.-J., Li, T., Yang, J.-J., Li, X., Li, W.-Q., & Yu, J. (2026) · ACS Omega · doi:10.1021/acsomega.5c13612
The Management of Polycystic Ovary Syndrome in Adolescents with Obesity
Barber, T. M., Thadani, P., Niven, E. V., Kyrou, I., & Randeva, H. S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03639-8
“Notably, recently reported RCTs on adolescents with obesity randomized to placebo versus daily liraglutide (3 mg) [58] and weekly semaglutide (2.4 mg) [59], each combined with lifestyle management, revealed significantly greater reductions in BMI in the treatment arms of each.”
InfluentialSoliman, A. T., Alyafei, F., Alaaraj, N., Mohamed, S., Hamed, N., & Elsiddig, S. A. (2026) · Jurnal Gastrohepatologi Anak Indonesia/Archives of Pediatric Gastroenterology, Hepatology, and Nutrition · doi:10.58427/apghn.5.2.2026.106-120
Lischka, J., Torbahn, G., Vallis, M., Mörwald, K., Gomahr, J., Forslund, A., Stenlid, R., Manell, H., Bergsten, P., Geiersberger, S., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70122
“Semaglutide was discontinued in one patient due to non-adherence and in another due to the development of an eating disorder.”
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Dueñas, L. G. D., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Flores, H. M. V., Mendoza-Godoy, J. J., Zavaleta‐Gutiérrez, F. E., & Paz‐Ibarra, J. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.118730
Stenlid, R., Cerenius, S. Y., Torbahn, G., Aydın, B. K., Ciba, I., Vilén, H., Mörwald, K., Geiersberger, S., Roomp, K., Cadamuro, J., et al. (2026) · Obesity Facts · doi:10.1159/000552826
Childhood Obesity: Epidemiology, Risk Factors, Prevention, and Emerging Treatment Strategies
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001359
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
“25 ● However, some patients experience increased anxiety related to appetite suppression and rapid weight loss.”
Rode, J. B., Wolf, J. M., Bolan, P. J., Palzer, E. F., Rudser, K. D., Aboobacker, S., Fox, C. K., Kelly, A. S., & Ryder, J. R. (2026) · Childhood Obesity · doi:10.1177/21532176261457202
“28,29 Resmetirom, the only FDA-approved therapy for adults with MASH and moderate to advanced fi brosis, has been shown to lead to complete resolution of MASH in 25.9% – 29.9% of patients but has yet to be evaluated in pediatric populations.”
InfluentialSelf-citationLuo, L., Huang, T., Yan, Z., Qi, Y., Wei, Q., Wang, H., Liu, N., Xuan, Y., Chen, Y., Zhao, J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70986 · Cited by 2
Pediatric Metabolic and Bariatric Surgery
Fleming, M. A., Morales, F. L., Inge, T. H., Reichard, K. W., & Michalsky, M. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_65
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
“…to other patient populations—including individuals with type 2 diabetes, those with lower BMI categories (class I and II obesity, overweight), and paediatric populations—would broaden the clinical applicability of incretin-guided pharmacotherapy [90]. https://doi.org/10.3390/diagnostics16131979”
InfluentialGLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns
Haider, M. A., & Javed, H. (2026) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2026.06.017
Prediabetes in children and adolescents: what do we need to know?
Jang, K. M., & Zeitler, P. S. (2026) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2550222.111
Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study
Pascu, B. M., Bojoga, I., Balanescu, A., Balanescu, P. C., & Gherghina, I. (2026) · Metabolites · doi:10.3390/metabo16070460 · Cited by 2
GLP-1 receptor agonists in pediatric obesity
Abodi, M., Agostoni, C. V., & Mazzocchi, A. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.010
Li, Y. C., Xu, X., Tuersun, A., Fan, X., Qin, M., Zhao, X., Abuduaini, S., Xing, H., & Chen, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108333 · Cited by 1
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Batra, K., Khubchandani, J., Batra, R., & Ali, S. A. (2026) · Diabetology · doi:10.3390/diabetology7080144
Tirzepatide for Severe Obesity in Adolescents Without Diabetes
Yehia, R., Patel, P., Sousa, E., & Vidmar, A. P. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.013
CONTEMPORARY MANAGEMENT OF PEDIATRIC OBESITY: A NARRATIVE REVIEW
Modrzejewska, W., Lamparski, Ł., Szmit, G., Wcisło, Z., Basak, W., Chmielewska, M., Piekarska, P., Purwin, A., Siwiec, K., Kulach, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5342
Thorsteinsdóttir, S., Jónsdóttir, B., Olafsdottir Anna, S., Arnarsdottir, H. B., Hallgrímsdóttir, S., Brynjólfsdóttir, B., & Helgason, T. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70139
“Safety data and adverse events were not systematically captured; children discontinuing treatment before 18 years of age may have experienced commonly reported gastrointestinal side effects [22, 34] that prevented continuation.”
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
“Liraglutide was associated with a 4.6% reduction in body mass index (BMI) compared with placebo, with 26% of the population achieving a 10% reduction in BMI [78].”
InfluentialObesidade na infância e adolescência
Rehme, M. F. B., Machado, M. S. C., Souza, I. F., Araújo, E. D. S. P., Salomão, C. B., Marinho, M. V. F. W., Freitas, I. C. F., & Gonçalves, K. A. G. (2020) · Femina · doi:10.61622/0100-72544810202001
Herstowska, M., Przygocka-Pieniążek, A., Lejk, A., Burzyński, J., Myśliwiec, M., & Kaska, Ł. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166139
Taki‐Eldin, A., Lotfy, A., El-Soudani, M., Ghaly, M. A., Eltaweel, M. M., Ghalwash, E. T., Elalfy, T., Kandel, A. M., Sadek, Z. M. A., & Ahmed, A. N. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100315 · Cited by 1
“…sensitivity, and reduce hepatic steatosis, each of which directly influences the outcome metrics central to bariatric effectiveness studies [11,12] Failure to control for this exposure in any study comparing adolescent and adult bariatric outcomes risks attributing GLP-1 RA-related…”
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
Well-being-centred perspective on childhood obesity
Hirsch, A. (2026) · JME Practical Bioethics · doi:10.1136/jmepb-2026-000164
Pediatric Obesity and Obstructive Sleep Apnea
Jones, H., Tayara, A., Baldassari, C. M., & Anne, S. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.06.003
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“It is approved for obesity management starting from 12 years of age [23].”
InfluentialBiliary Events and GLP-1 Receptor Agonist Therapy in Adolescents and Young Adults
Filho, J. R. D. O., Papadakis, L., Collins, R. A., Shnawa, G. N., & Griggs, C. L. (2026) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2026.3918
Kalagi, F., Bah, S., & AlGindan, Y. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100331
“These findings are consistent with pediatric studies reporting gastrointestinal adverse events as the most common treatment-related effects, while uncertainty remains regarding potential long-term effects on growth and pubertal development [15,17].”
Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019–2026
Orandi, B. J., Patel, S. S., Messito, M. J., Mankowski, M. A., Segev, D. L., & Massie, A. B. (2026) · PEDIATRICS · doi:10.1542/peds.2026-077048
A new therapeutic era in childhood and adolescent obesity: opportunities and future challenges
Molina-Giraldo, P., Suárez-Ortega, L., & Ramon‐Krauel, M. (2026) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2026.504194
O’Brien, E. M., Gallop, R., Washburn, M., Dumas, A., Como, N., Kilungya, F., Willi, S. M., & Lin, E. E. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.07.016 · Cited by 2
Emerging Therapeutic Strategies for Child and Adolescent Obesity: A Narrative Review
Oliaro, T., & Federico, A. (2026) · Nutrients · doi:10.3390/nu18203449
“Cholelithiasis was reported in 4% of participants receiving semaglutide and in none receiving placebo [18,19].”
InfluentialLindberg, L., Beck, R. H., Danielsson, P., Nielsen, T., Abdalla, A., Ekstedt, P., Chaturvedi, D., Qahtani, N. A., Marcus, C., & Deeb, A. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-07623-7
“Recent advances, including pharmacological treatments for adolescents, have shown promising results [16–18], but face challenges such as financial and accessibility barriers.”
Self-citationSaid, J., Liegl, M., Pan, A. Y., & Dabrowski, E. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0227
“Childhood and adolescent obesity has reached epidemic proportions worldwide, with projections estimating that more than 250 million children and adolescents will be a ff ected by 2030 [1, 2].”
InfluentialMyśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188191
“…trials of liraglutide and semaglutide have demonstrated clinically meaningful reductions in BMI, comprehensive assessment of body composition using dual-energy X-ray absorptiometry (DXA) (GE HealthCare, Chicago, Illinois, United States)has not been a primary endpoint in these studies [43,47].”
InfluentialChiu, C.-F., Chou, C., Hu, S.-W., Huang, K., Wu, Y.-L., Wu, H.-F., Liu, Y.-L., Yang, Y.-C., Chen, H., & Yeung, C. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.09.001
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
Zhong, Q., Yang, A. L., & Volic, I. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00999-4
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.